Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Average PT from Analysts

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been assigned an average recommendation of “Buy” from the eight brokerages that are presently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $71.40.

Several research analysts recently commented on the stock. Leerink Partnrs upgraded shares of Arcturus Therapeutics to a “strong-buy” rating in a report on Monday, August 12th. Leerink Partners began coverage on shares of Arcturus Therapeutics in a report on Monday, August 12th. They set an “outperform” rating and a $70.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research report on Tuesday, October 1st.

Arcturus Therapeutics Stock Up 4.1 %

Arcturus Therapeutics stock opened at $21.46 on Friday. The stock has a market capitalization of $577.96 million, a PE ratio of -5.49 and a beta of 2.61. Arcturus Therapeutics has a twelve month low of $17.52 and a twelve month high of $45.00. The company has a 50 day moving average of $20.97 and a 200-day moving average of $25.80.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($1.85) by $1.21. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. The business had revenue of $49.86 million during the quarter, compared to analysts’ expectations of $21.00 million. During the same quarter in the prior year, the company posted ($1.98) earnings per share. Equities analysts anticipate that Arcturus Therapeutics will post -2.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Arcturus Therapeutics

Several large investors have recently modified their holdings of the stock. CANADA LIFE ASSURANCE Co raised its position in shares of Arcturus Therapeutics by 10.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 428 shares during the period. Hennion & Walsh Asset Management Inc. raised its position in shares of Arcturus Therapeutics by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 31,930 shares of the biotechnology company’s stock valued at $1,078,000 after purchasing an additional 778 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Arcturus Therapeutics by 5.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 17,004 shares of the biotechnology company’s stock valued at $575,000 after purchasing an additional 922 shares during the period. Russell Investments Group Ltd. bought a new position in shares of Arcturus Therapeutics in the first quarter valued at about $40,000. Finally, Public Employees Retirement System of Ohio raised its position in shares of Arcturus Therapeutics by 63.8% in the first quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company’s stock valued at $156,000 after purchasing an additional 1,800 shares during the period. 94.54% of the stock is owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.